Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation
Authors' conclusion
Combination therapy of SGLT2i and DPP4i improves glycaemic control in T2D, with enhanced DPP4i efficacy noted in Asian populations, highlighting its role in personalized diabetes management for these patients.
Study context
- Population
- Patients with T2D in randomized controlled trials (RCTs) published through January 2024, with focus on Asian subpopulations
- Participants
- 7,588 patients17 RCTs
- Comparison
- SGLT2i/DPP4i combination vs DPP4i or SGLT2i monotherapy
- Outcome
- HbA1c changes
Methodological detailssubgroup analyses by baseline haemoglobin A1c (HbA1c) and race (Asian vs non-Asian)
- Subgroup analyses by baseline HbA1c and race (Asian vs non-Asian)
Pooled result
As reported in the abstract
HbA1c change
MD, % (95% CI)
SGLT2i/DPP4ivs DPP4i
−0.57(−0.67 to −0.46%)
SGLT2i/DPP4ivs SGLT2i
−0.46(−0.55 to −0.38%)
Further pooled results
| Outcome | MD (kg) (95% CI) | |
|---|---|---|
| Body weightSGLT2i/DPP4ivs DPP4i | −1.57 (−1.93 to −1.20 kg) | |
| −2−101Difference, kg (linear scale) |
Body weight
- No significant effect on body weight with SGLT2i/DPP4i vs SGLT2i
HbA1c reduction from adding DPP4i, by race subgroup
- Asian participants: MD
- −0.55% (95% CI −0.71 to −0.39)
- Non-Asian participants: MD
- −0.38% (95% CI −0.46 to −0.31)
- Efficacy more pronounced in Asian participants
Safety
- Similar risk of hypoglycaemia with combination vs both monotherapies; no statistically significant differences
Original publication
Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta‐analysis with focus on an Asian subpopulation. Diabetes Obes Metab. Published 24 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →